Drugs / herpes simplex thymidine kinase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00005025 | Jun 2000 → ? | fallopian tube cancer, ovarian cancer, peritoneum cancer | John Stoddard Cancer Center at Iowa Methodist Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | herpes simplex thymidine kinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005025 ↗ |
| Known as | HSVtk | “herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC)” NCT00005025 ↗ |
| Route | Other | “Patients receive herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) IP over 15-60 minutes on day 0” NCT00005025 ↗ |